^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    ClearSEEK™ PIK3CA Panel

    Company:
    Agena Bio
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    over1year
    Detection of Somatic Variants in Breast Cancer Specimens Using the Novel AGENA ClearSEEK PIK3CA Panel on the MassARRAY System (AMP 2022)
    "The PI3K inhibitor alpelisib has been recently approved for the treatment of HR+/HER2- metastatic breast cancer with PIK3CA mutations (PIK3CAmut)... The AGENA ClearSEEK PIK3CA Panel combines both low DNA input and hands-on time requirements with accurate data assessment and provides a high-sensitive and reliable tool to perform PIK3CA analysis of clinically actionable mutations in breast cancer tumors."
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 negative • PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E542K • PIK3CA E545 • PIK3CA E542
    |
    therascreen® PIK3CA RGQ PCR Kit • ClearSEEK™ PIK3CA Panel
    |
    Piqray (alpelisib)